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Background: Adverse drug reactions (ADR) are a public health issue, due to their great
impact on morbidity, mortality, and economic cost.
Objective: We aimed to study the percentage of patients admitted urgently as a result of
an ADR, considered serious adverse event, or medication error. Also, we intended to
identify possible risk factors which would lead to improvements in the prescription and use
of medications.
Methods: This is a retrospective observational study conducted during February 2019,
including patients admitted through the emergency department in our hospital. We
evaluated the medical records of those with suspected ADR diagnoses to perform a
descriptive analysis of the demographic characteristics. Moreover, after applying the
Spanish Pharmacovigilance System causality algorithm, we performed a descriptive
analysis of the identified ADR and the drugs involved. We also investigated those cases
suspected of being a medication error.
Results: During the study period, 847 patients were urgently hospitalized. From those, 71
(29 women and 42 men) were admitted due to an ADR (8.4%, 95% CI 6.5%–10.3%). The
mean age was 73 ± 15.9 years old and the mean number of prescribed medications was
7.3 ± 3.6 drugs/patient on admission. The most frequent ADR were opportunistic
infections due to antineoplastic and immunomodulator drugs, and bleeding due to
antiaggregants and anticoagulants. Five suspected medication errors occurred, being
the incidence 0.6% (95% CI 0.08%–1.12%) of total admissions.
Conclusions: 8.4% of urgent admissions were attributed to an ADR. Age (75% of
patients were ≥ 65 years old), comorbidities and polymedication were the main riskin.org May 2020 | Volume 11 | Article 7341
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Frontiers in Pharmacology | www.frontiersfactors. Although medication errors had a very low incidence (0.6% of urgent admissions),
they were preventable and should be considered as a focus for action.Keywords: adverse drug reaction, medication error, urgent admission, pharmacovigilance, emergency departmentINTRODUCTION
Drugs are capable of preventing, relieving, or improving human
health. Mostly, they are substantially beneficial and have meant
the greatest advance for society, improving human quality of life,
and life expectancy. However, drugs are not exempt from risks.
During clinical development, prior to marketing authorization,
the number of patients exposed to investigational drugs is very
low. Therefore, rare adverse reactions are not correctly identified.
For this reason, the pharmacovigilance strategy of adverse events
monitoring in daily clinical practice is a cornerstone for prompt
adverse drug reaction (ADR) identification and prevention.
An ADR is any unintended, harmful response to a drug. It
includes not only unplanned harmful effects resulting from the
authorized use of a drug at normal doses, but also related to
medication errors and uses outside the terms of the marketing
authorization, including misuse, overdose and drug abuse
(Spanish Ministry of Health). ADR are a public health issue,
due to their great impact on morbidity, mortality and economic
cost (Patel et al., 2007). Several meta-analyses have studied the
frequency of ADR as a cause of hospitalization in Western
countries, raising a range of 3.7%–5.3% of hospital admissions
caused by an ADR (Pedrós et al., 2014). However, there is still a
considerable variability between studies since some report a rate
of 4.2% (Pedrós et al., 2014), 4.8% (Garijo et al., 1991), 6.7%
(Lazarou et al., 1998), or even 8.8% (Ahern et al., 2014) of ADR-
caused hospital admissions. This inconsistency might be due to
different study design, the type of events studied, the definition of
ADR used, the methods of case identification, variations in the
causality algorithms, the study duration, etc.
In the USA, ADR are diagnosed in approximately 4.7% of
hospitalized patients. However, according to Crispo et al., many
cases are readmissions, patients who were discharged and who
are readmitted within 45 days as a result of an ADR (Crispo et al.,
2019). Indeed, the risk of suffering an ADR after discharge is five
times greater than the risk during hospitalization (Crispo
et al., 2019).
Some ADR may be due to medication errors. Namely,
incidents that were preventable and occur at any stage of the
use process, that can produce harm to patients. These include
errors in: prescribing, communication, labelling, packaging,
naming, preparation, dispensing, distribution, administration,
education, and monitoring. These errors often occur at several
levels at once, so they should be considered as system errors, and
never as human errors. It is estimated that for each hospitalized
patient there are 0.9 medication errors per day (Pastó-Cardona
et al., 2009). Certainly, between 44,000 and 98,000 deaths per
year were attributable to medical errors or failures in the health
system (Pastó-Cardona et al., 2009). However, a more recent
study estimated that 1.1% of deaths are due to medical errorsin.org 2which, extrapolated to all hospital admissions recorded in the
USA, reached 400,000 deaths per year, four times more than the
previously valued (Makary and Daniel, 2016). Currently, medical
errors are still one of the most important causes of death in the
USA, ranking third after cardiovascular diseases and cancer
(Makary and Daniel, 2016; Crispo et al., 2019).
Medication consumption is increasing in recent years,
consequently, ADR and medication errors might also be on the
rise. A high number of admissions can be attributed to ADR, in
which the patient’s health might be at risk or even cause life-
threatening situations. The impact of these ADR on public health
is noticeable on several levels: quality of health care, patient’s
quality of life, and economic expenditure.
For these reasons, we aimed to study the percentage of patients
admitted urgently as a result of a serious ADR, and how many are
due to medication errors. We aimed to identify possible patterns
and risk factors which would lead to improvements in drug
prescription, administration, consumption, and monitoring.
Therefore, the amount and seriousness of such ADR might
be reduced.MATERIALS AND METHODS
Study Population and Study Design
A retrospective observational study was conducted at the Clinical
Pharmacology Department of Hospital Universitario de La
Princesa, a third-level university hospital in Madrid (Spain). It
has approximately 564 beds and covers a population of 323,000
individuals. It offers all medical and surgical specialties, except
for pediatrics and obstetrics-gynaecology. The study period was
28 days and included all patients who were admitted trough the
emergency room during February 2019. Patients with scheduled
admissions, emergency observation stays, admissions of less than
24 h, and transfers from other centres were excluded.
Sample Size Calculation
For a 95% confidence level (CI), and an accuracy of +/- 2
percentage units, the number of medical records required for
the study was 507, with a population percentage predicted to be
around 5%. The percentage of non-assessable patients was
calculated to be 10%.
Given that the Emergency Department of Hospital
Universitario de La Princesa admits about 8,000 patients a
year, the information was collected over a period of 28 days
(approximately 600 admissions). From those, the medical
records of patients with suspected ADR were thoroughly
reviewed for causality assessment and identification of
medication errors.May 2020 | Volume 11 | Article 734
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All admissions with a suspected ADR-related diagnosis,
according to a previously pre-defined list (see Pedrós et al.,
2014), were reviewed to assess whether there was any suspected
drug responsible for the admission. The pre-defined list includes
all diseases or syndromes potentially caused by drugs.
Demographic variables were collected from patients with
suspected ADR: age, sex, weight, and height, and diagnosis at
admission. In addition, special attention was paid to the usual
treatment of each patient, analysing each drug to detect the
potential responsibility for the ADR.
In every patient with a suspected ADR, the causality
algorithm published by the Spanish Pharmacovigilance System
(SEFV) (Aguirre and Garcıá, 2016), which is a modification of
the one published by Karch and Lasagna (Karch and Lasagna,
1977), was applied to each suspected drug by two investigators
(GM and BG) and when the score was different an agreement
was sought.
The SEFV algorithm comprises seven criteria, which are
assessed trough every drug-adverse effect pair: (1) Time
sequence. Chronology between the start of treatment with the
suspected drug(s) and the appearance of the adverse effects. The
compatibility of this sequence with the mechanism of action of
the drug and/or with the physio-pathological process of the
adverse effect is analyzed; (2) Previous knowledge of the adverse
effect in the literature; (3) Effect of withdrawal: evolution of the
adverse effect after withdrawal of the suspected medication;
(4) Re-exposure: effect of re-administration of the suspected
medicinal product; (5) Alternative causes: existence of an
alternative cause, a non-pharmacological explanation for the
observed effects; (6) Contributing factors favouring the causal
relationship (e.g., renal failure and relative overdose of a drug
with predominantly renal elimination); (7) Complementary
exploration: drug levels in a biological fluid, biopsy, positive
radiological examinations, positive specific skin tests, etc.
Based on the obtained scored, the causal relationship was
classified as: unrelated (< 1), conditional (1–3), possible (4–5),
probable (6–7), and defined (> 7) (Aguirre and Garcıá, 2016).
Only those adverse events classified as possible, probable, or
defined were considered drug-related. Therefore, possible,
probable, or defined adverse events were merged into the
category ADR, so they were grouped together for the analysis.
Ethics
The project obtained its approval from the Ethics Committee for
Research on Medicines (CEIm) of Hospital Universitario de La
Princesa. As all the information was registered from the
electronic medical record without interviewing the patients, it
was not necessary to ask for the patients’ informed consent.
The researchers respected the confidentiality of every data
obtained during the conduct of the study. No data were collected
that could identify the patients.
Data Collection and Information Sources
The information was registered only from the hospital’s
computer system database, by reviewing patients’ medical
records. There was no need to interview patients to obtainFrontiers in Pharmacology | www.frontiersin.org 3additional information; therefore, informed consent was not
required. Data collection was performed without causing any
alteration in the information system or any variation in usual
clinical practice.
Data Analysis
The statistical analysis was accomplished using the SPSS 22.0
statistical software (SPSS Inc., Chicago, Illinois) and Microsoft
Excel 2010. The main variable was the incidence of ADR-
caused hospital admission. The percentage of ADR due to
medication errors was also calculated. The characteristics of
patients admitted by an ADR and the main drugs involved
were described.RESULTS
Suspected ADR and Patients’
Characteristics
During thewhole studyperiod, 847patientswere admitted urgently
to Hospital Universitario de La Princesa. These patients’ diagnoses
were reviewed according to the list publishedbyPedrós et al. (2014).
In all, we found 232 patients whose admission could be due to an
ADR. Then, the exhaustive review of these 232 patients’ medical
records yielded the necessary information to establish the ADR-
related diagnosis.
After this medical records revision, the number of patients
who could have possible ADR was reduced to 95. The remaining
patients were excluded due to incompatibility with the diagnosis
of an ADR. The criteria for exclusion were: not receiving routine
treatment or no medication suspected, the time sequence was
found to be within a post-operative range and in relation to the
surgery they had undergone, or the condition on admission was
triggered by a community-acquired infection, with the exception
of opportunistic infections.
The diagnoses of suspected ADR are shown in Table 1.
The most frequent were haemorrhages or hematomas
(20%), opportunistic infections (16.8%), and heart failure
decompensation (16.8%).TABLE 1 | Suspected adverse drug reaction (ADR) diagnoses in our study
population of urgent admissions (n = 847).
Diagnosis N Percentage
Haemorrhages/hematomas 19 20.0
Opportunistic infections 16 16.8
Heart failure decompensation 16 16.8
Vomiting or diarrhoea 9 9.5
Low level of consciousness or bronchial aspiration 8 8.4
Arrhythmias or heart block 7 7.4
Renal failure 6 6.3
Autolytic attempt 3 3.2
Pulmonary thromboembolism 2 2.1
Others 9 9.5
Total 95 100May 2020 | Volume 11Others category include individual cases of: respiratory failure, intoxication, hypotension,
exanthema, hyponatremia, dehydration, pancreatitis, liver toxicity, and syncope.| Article 734
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with a mean age of 73 ± 15.9 years old, median age 75 (range 26–
100) years old, 75% of patients were older adults (> 65 years old),
with a similar distribution between both sexes. Regarding
cardiovascular risk factors, 70.5% presented one or more, being
high blood pressure (58.9%), dyslipemia (36.8%), and diabetes
mellitus (16.8%) the more frequent.
About the unhealthy lifestyle habits: 30 had smoked and 13were
still smoking, accumulating an averagepack-years indexof 45.2 and
a standard deviation of 28.9 (ranging from 2 to 100). Regarding the
history of alcohol abuse, we found 13 patients who showed an
important consumption, 6 of which no longer maintained it in the
present. Only 15 patients admitted for suspected ADR did not
present any cardiovascular risk factor or unhealthy lifestyle. It is
worth noting that this group of patients received an average of 7.3
drugs per person, with a range of 1 to 17.
A total of 155 drugs that could be responsible for the adverse
reactions in the study were collected from the 95 patients. We
found that 46 patients had only one suspected drug, 39 patients
had 2 suspected drugs and 10 patients had 3 or more.
The Spanish Pharmacovigilance System causality algorithm
(Aguirre and Garcıá, 2016) was applied to each of the suspected
drugs. As shown in Tables 2 and 3, if we consider an ADR thoseFrontiers in Pharmacology | www.frontiersin.org 4events with a possible, probable or definite causal relationship
(score ≥ 4) for at least one drug, we found that 71 patients
(74.7%) had been admitted as a result of an ADR. Besides, more
than one drug could have been involved in the reaction since the
causality algorithm revealed 47 possible, 47 probable, and 1
definite causal relationships. Table 3 depicts the main drugs
categories found in our study population, being the most
frequent antihypertensives and diuretics (18.7%) and
antineoplastics (16.8).
Therefore, in the population of our sample, the percentage of
urgent admissions as a result of an ADR is 8.4% with a 95% CI of
6.5%–10.3%.
From the 71 patients admitted for an ADR, 29 were women
and 42 were men, with an average age of 73 years old and a mean
intake of 7.3 drugs per patient. These results were similar to those
from the total of 95 patients with suspected ADR. However, the
incidence of cardiovascular risk factors and unhealthy lifestyle
habits were slightly higher in this group of patients with ADR:
61% had high-blood pressure, 38% dyslipemia, and 20% diabetes
mellitus. Moreover, 13% smoked and 37% had smoked in the
past (accumulating an average pack-years index of 48 (ranging
from 2 to 100), 13% had an abuse alcohol history. Finally, only
nine patients lack any cardiovascular risk factor or
unhealthy lifestyle.
Table 4 shows the incidence of ADR in each group of drugs.
The majority of ADR were found in the antineoplastics group
(20%), followed by the category “others” (12.6%), antiplatelet
agents (11.6%), and antihypertensives and diuretics (10.5%).
None of the ADR was due to an allergy.
Medication Errors
We found five potential medication errors (Table 5), three of
which belonged to the group of 71 patients who had been
admitted for an ADR, i.e., 4.2%. And of the total patientsTABLE 2 | Evaluation of causality of the drugs received by the patients with
suspected adverse drug reaction (ADR) (n = 95).






Total 155 100TABLE 3 | Drugs potentially involved in the adverse drug reaction (ADR) and their categorization in each causal group.
Type of drug Causality Total
Unrelated Conditional Possible Probable Defined
Antihypertensives and diuretics 3 16 5 5 0 29
Antineoplastics 0 7 7 12 0 26
Immunomodulators 2 3 2 5 0 12
Antiplatelet agents 0 0 2 8 1 11
Anti-epileptics 2 3 5 0 0 10
Atypical antipsychotics 0 3 5 2 0 10
Anticoagulants 0 0 6 1 0 7
Beta-blockers 0 2 4 0 0 6
NSAIDs 0 2 3 1 0 6
Antibiotics 0 2 0 4 0 6
Antidepressants 0 4 0 0 0 4
Antiretrovirals 0 1 0 3 0 4
Benzodiazepines 1 2 0 0 0 3
Opioids 0 0 1 1 0 2
Others 1 6 7 5 0 19
Total 9 51 47 47 1 155May 2020 | Volume 11 | ArticNSAIDs, nonsteroidal anti-inflammatory drugs. The category “others” include: zolpidem, pentoxifylline, propofol, digoxin, desogestrel/etinylestradiol, granisetron, hydroxychloroquine,
memantine, rivastigmine, galantamine, lithium, haloperidol, fenofibrate, levothyroxine, tamsulosin-dutasteride, and the inhaler formoterol-beclomethasone.le 734
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0.08%–1.12%).
In two patients, the event occurred when the drug was
withdrawn (Septrin® and Sintrom®). Another patient had a
grade 2 prothrombotic syndrome and possibly needed
anticoagulation. Another patient presented valproic acid
poisoning due to a duplication of the prescription (a
prescription of 600 mg every 12 h and another of 1,000 mg
every 12 h) and the last one was diabetic and did not inject the
prescribed insulin due to ignorance of the possible consequences.DISCUSSION
Adverse Drug Reactions
A serious ADR is any adverse reaction that results in death, may
be life-threatening, requires hospitalization of the patient or
prolongation of existing hospitalization, causes significant or
persistent disability or invalidity, or constitutes a congenital
anomaly or birth defect (Spanish Ministry of Health, 2013). So,
all ADR considered in this study are serious adverse reactions.Frontiers in Pharmacology | www.frontiersin.org 5Our research revealed an ADR-related urgent admission rate
of 8.4% (95% CI: 6.5%–10.3). Although our results resembled of
those from Ahern et al, who found a rate of 8.8% of urgent
admissions attributable to an ADR in Irish population (Ahern
et al., 2014), our results are notably higher than the previously
reported for Spanish population (4.2%–4.8%) (Garijo et al., 1991;
Pedrós et al., 2014). However, the overall incidence of serious
ADR (causing hospitalization) in the US was reported to be 6.7%
(95% CI 5.2%–8.2%) in the meta-analysis performed by Lazarou
et al. already in 1998 (Lazarou et al., 1998). Other previous
studies evaluated similar settings, but with different study design,
such as the one by Taylor et al. (2020), which is a prospective
study that evaluates problems related to medication before,
during and after the patient goes to the emergency department.
This study does not analyze urgent hospital admissions caused
by ADRs, which is the main objective of our study. Moreover, a
recent study by Just et al. (2020), although describes ADRs
leading to emergency department visits and the drugs related
with them, it provides different data from ours since they did not
calculate the rate of ADR-caused hospital admissions.
Recently, Schurig et al. calculated the percentage of suspected
ADR cases among all patients presenting to the emergency room
during a 30-day period of observation, accounting for 6.5% of the
total visits (Schurig et al., 2018). However, this study does not
provide data about hospital admissions. Although similar to
ours, it does not show how many of the admitted patients are
due to ADRs and it does not evaluate medication errors.
The study by Hamed et al. only collected 159 cases of ADRs
from 113,272 emergency department visits (Hamed et al., 2017),
accounting for the 0.14%, which might be insufficient. In our
study, 11% of the urgent hospital admissions were categorized as
possible ADR-caused that reduced to 8.4% after applying the
causality algorithm. Moreover, this study does not provide data
on the incidence of ADR-caused hospital admissions.TABLE 4 | Drugs suspected to cause urgent hospital admission by adverse drug reaction (ADR) in our study population.
Type of drug Number of
patients
Percentage Description of ADR
Antineoplastics 19 20.0 Opportunistic infections: 18; vomiting or diarrhea: 1.
Antiplatelet agents 11 11.6 Haemorrhages/hematomas: 11.
Antihypertensives
and diuretics
10 10.5 Heart failure decompensation: 5; renal failure: 4; arrhythmias or heart block: 1
Anticoagulants 7 7.4 Haemorrhages/hematomas: 6; pulmonary thromboembolism: 1.
Immunomodulators 7 7.4 Opportunistic infections: 7.
Atypical
antipsychotics
7 7.4 Low level of consciousness or bronchial aspiration: 6; liver toxicity: 1.
Anti-epileptics 5 5.3 Low level of consciousness or bronchial aspiration: 4; vomiting or diarrhea: 1.
Beta-blockers 4 4.2 Heart failure decompensation 3; arrhythmias or heart block: 1.
NSAIDs 4 4.2 Heart failure decompensation: 1; renal failure: 2; hyponatremia:1.
Antibiotics 4 4.2 Haemorrhages (haemorrhagic colitis): 1, vomiting or diarrhea: 2; exanthema: 1.
Antiretrovirals 3 3.2 Vomiting or diarrhea: 2; pancreatitis 1.
Opioids 2 2.1 Low level of consciousness or bronchial aspiration: 1; vomiting or diarrhea: 1.
Others* 12 12.6 Heart failure decompensation: 3; low level of consciousness or bronchial aspiration: 4; pulmonary
thromboembolism: 1; vomiting or diarrhea:1; arrhythmias or heart block: 1; hypotension: 1; pancreatitis 1.
Total 95 100NSAIDs, nonsteroidal anti-inflammatory drugs. *Drugs: tamsulosin-dutasteride (Heart failure decompensation), zolpidem, memantine, rivastigmine and galantamine (low level of
consciousness or bronchial aspiration), contraceptive (pulmonary thromboembolism), granisetron (diarrhoea), digoxin (arrhythmia), propofol (hypotension), and fenofibrate (pancreatitis).TABLE 5 | Medication errors found in our study population of patients urgently








Anticoagulant Deep vein thrombosis Absence of
prescription
Insuline Ketoacidotic coma Misuse
Valproic acid Intoxication Duplicate prescriptionADR, adverse drug reaction.May 2020 | Volume 11 | Article 734
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and risk factors of ADR attended in the emergency department
that are related to a specific drug, such as Tanreqing injection, a
traditional Chinese medicine commonly used in China (Li et al.,
2020). This study is not comparable to ours, which provides
much more general data that can be more easily extrapolated to
the general population.
Finally, the relevant study by Budnitz et al. described
emergency hospitalizations for recognized ADR in older adults
(Budnitz et al., 2011). This study differs from ours mainly in the
study design, since it was carried out from an electronic registry
without systematically reviewing all the patients admitted as we
did. For this reason, our data is more reliable, especially if we
want to calculate the incidence of admissions caused by ADRs.
Moreover, it was conducted 9 years ago, so it is necessary to
continue providing data.”
The fact that our rate is higher in our population compared to
the reference Spanish study, could be explained by some
differences in the study population included. Firstly, our
population is less heterogeneous than the general, since our
hospital does not attend children but attends a majority of aged
population, compared to other hospitals from the same region of
Madrid. In our study, the mean age was 73.0 ± 15.9, ranging from
26 to 100 years old. As previously known, age is itself a risk factor
for deve loping ADR due to pharmacokinet ic and
pharmacodynamic changes, and the pace of population ageing
is increasing. These facts explain the high prevalence of
comorbidities and polymedication found in our study (7.3
drugs/person, with a range of 1–17), also considered risk
factors themselves (Leendertse et al., 2008). However, the study
by Pedrós et al. included a similar population with a mean age of
75 years old (Pedrós et al., 2014). Indeed, our results confirm
those from Kojima et al., who reported that in geriatric patients
the incidence of ADR is significantly associated with
polypharmacy (especially ≥7 drugs) and emergency admission
(Kojima et al., 2019).
There were a few cases difficult to assess, as the relation
between immunosuppressants (steroids) and the appearance of
opportunistic infections, since in many cases these ADR were not
displayed in the drug’s label. To avoid possible bias, we included
those cases in the study and applied the causality algorithm.
Moreover, the same occurred when analyzing the hospital
admissions due to reactions such as decompensation of heart
failure, low level of consciousness, arrhythmias, or renal failure.
Those cases were controversial, since these reactions are very
frequent alterations in older adults and can be explained by the
natural evolution of their basal pathology. Again, to avoid
possible bias, it was decided to give the same value to both
variables when applying the causality algorithm. In admissions
caused by a haemorrhage, those triggered by a hypertensive crisis
or trauma were excluded, but those that arise spontaneously
during antiaggregation or anticoagulant therapy were analysed,
all finally categorized as ADR. Finally, autolytic attempts are
included within the definition of ADR in two situations: (i) cases
in which a drug may promote suicidal ideation and (ii) thoseFrontiers in Pharmacology | www.frontiersin.org 6cases in which the autolytic attempt is carried out with a drug
overdose. For this reason, benzodiazepine intoxication was
added to the list of established ADR.
This higher degree of case unravelling and recognition, along
with a wider definition of an ADR, could also have led to a higher
ADR-related admission rate (8.5% vs. 4.2%–4.8% from previous
studies) (Garijo et al., 1991; Pedrós et al., 2014). Further
approaches are needed to shed light on this controversial rate.
Regarding sex, the study by Ruiter et al. specify that being a
female is a risk factor for the development of an ADR (Ruiter
et al., 2012). However, in both our study and the one performed
by Pedrós et al., no significant differences between sexes were
found (Pedrós et al., 2014). In our study, from the 71 patients
admitted for an ADR-related condition, 42 were men. However,
we are not able to determine that being a male is a risk factor for
ADR development.
The most frequently reported reactions were opportunistic
infections, caused by antineoplastic and immunomodulatory
treatments, and haemorrhages or hematomas, as a consequence
of antiaggregation and anticoagulant therapy. Unlike the study
by Pedrós et al., which was carried out in a hospital where there
was no oncology service (Pedrós et al., 2014). This could
explain the absence of opportunistic infections in their study,
in favour of a higher incidence of renal and urinary disorders
followed by bleeding of digestive origin (Pedrós et al., 2014).
In the study by Zhang et al., anticoagulants were the
most common medications contributing to ADR-related
hospitalisation, followed by opioid analgesics (Zhang et al.,
2019). In concordance to our results, the study by Just et al.
reported that antineoplastic/immunomodulating agents had the
highest odds ratio for being suspected for an ADR, followed by
antithrombotics (Just et al., 2020). Schurig et al. also reported
antithrombotic and antihypertensive agents as the most
commonly suspected cause of ADR (Schurig et al., 2018).
Furthermore, it should be noted the high number of ADR
possibly caused by antihypertensive and diuretic drugs that may
be linked, for example, to a change in the patient’s prescriptions
by the primary care physician, with potential adverse
interactions with existing medications. In the study by
Ognibene et al., diuretics were the most common ADR causing
drugs, followed by antithrombotics and central nervous system-
active drugs (Ognibene et al., 2018). However, in our study, after
applying the causality algorithm, we observed that they were not
the real cause of the adverse reactions a priori attributed to them,
as described in other study (Ahern et al., 2014). Moreover,
suspected ADR from antidepressants or benzodiazepines have
been discarded. While, in the case of antibiotics, antiretrovirals,
and beta-blockers, they have proved to be responsible for almost
all reactions that were attributed to them.
All the drugs included have been marketed for a long time and
are considered safe. However, any drug is free from causing an
ADR, especially when prescribed to those patients more susceptible
of developing an adverse reaction, such as older adults. In addition,
this type of patients usually receives several concomitant
treatments, which might interact between them. Therefore,May 2020 | Volume 11 | Article 734
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patients, by monitoring their pathologies and reducing the
number of prescribed drugs to the minimum possible. Almost
45% of the ADR have been reported to be preventable (Al Damen
and Basheti, 2019). Certainly, insufficient monitoring was the cause
of almost 30% of those (Al Damen and Basheti, 2019).
It is of great importance the role of primary care physicians
(PCPs) in the prevention of ADR. Most of PCP are aware of the
importance of a close attention when prescribing several drugs to
a patient (Raguz Lucic et al., 2018). However, it must be taken
into account the difficultness of properly supervise the use of
multiple medications due to the potential ADR and drug-drug
interactions (Ko et al., 2008). A recent study by Raguz Lucic et al.
found that 92.8% of surveyed PCPs explained the possible ADR
and drug-drug interactions to special groups of patients (i.e.,
pregnant women or elderly patients) (Raguz Lucic et al., 2018).
However, from 10 questions regarding their knowledge about
drug-drug interactions and ADR, the median number of correct
response was 5 (range 4–7) (Raguz Lucic et al., 2018). Although
PCP are aware of the importance of counseling practices about
ADR and interactions (Raguz Lucic et al., 2018), further
formation is needed. Furthermore, also pharmacists could be
essential for monitoring the potential ADR in general practice,
being the collaboration between PCP and pharmacists of mutual
benefit (Shulman et al., 1981).
Moreover, pharmacovigilance is an area where PCP should be
proactive and remind doctors of their moral duty to inform
possible ADR. Without a good pharmacovigilance system, it
would be impossible to assess long-term adverse effects of drugs
and other possible ADR that would not be highlighted in time to
avoid a hospital admission or even save lives.
Medication Errors
In Spain, there are 1.4 medication errors per hospitalized patient,
around 23.6 per 100 admissions per year, 6.1 adverse effects, and
5.5 potential adverse effects per 100 admissions, although only
5% cause appreciable damage (Pastó-Cardona et al., 2009). In
our study, the incidence of hospital admission due to a
medication error reached only 0.6% (95% CI 0.08%–1.12%),
much lower than 4.7%–5.3% previously reported (Pastó-
Cardona et al., 2009). In our study, we found 1 case of double
prescription, much lower than the 10 cases (6.3%) found in a
previous study (Hamed et al., 2017).
A recent study in 6,427 ADR patients found that a
preventable ADR was present in almost 20% of the cases,
especially in patients aged ≥70 years (Schmiedl et al., 2018).
However, only 3 of 71 patients admitted by an ADR suffered a
medication error (4.2%) in our study.
The errors in the prescription or use of drugs, such as those
we have detected in this study, could be solved with measures
available to health personnel. These measures include resources
and time investment for a deeper education of patients about
their disease, the establishment of double control over
prescriptions, as well as encouraging the use of a single
prescription module (already in use in Community of Madrid,
Spain). Currently there are no adequate tools to assess the risk of
ADR in primary care. Further research is needed on tools toFrontiers in Pharmacology | www.frontiersin.org 7identify high-risk patients for the prevention of ADR-related
hospital admissions (Parameswaran Nair et al., 2016).
When trying to avoid medication errors, it is vital to ensure
that the correct medication is prescribed for the correct patient,
in the correct dosage, via the correct route and timed correctly.
The Patient Safety Strategy of the Spanish National Health
System made a series of recommendations to promote the safe
use of medicines (Patient Safety Strategy of the National Health
System, 2015-2020). These recommendations include, among
others, (i) the implementation of electronic prescription
programs, including clinical decision support systems which
should be integrated into the information systems of the health
center, and available to all professionals involved in the patient
care; (ii) the standardization of preparation and administration
procedures of injectable drugs and parenteral nutrition; (iii) the
systematical review of the medication in chronic polymedicated
patients, to detect or prevent adverse events, ensure adequacy,
and improve adherence to treatment; (iv) the establishment of
specific interventions aimed at avoiding errors in medication
(training, dissemination of guidelines, etc.); (v) the development
of training actions for healthcare professionals on the safe use of
medicines, information and training programs for patients and
caregivers; (vi) promote notification as a tool to disseminate the
culture of patient safety.
Study Limitations
During the development of this work a series of limitations have
risen, such as the selection bias that might have occurred when
limiting the study to one month, in a single hospital in Madrid
and where, in addition, the population is slightly heterogeneous.
As a consequence, the data obtained could only be extrapolated
to a population with similar characteristics. Although the sample
is relatively small (847 patients), it is superior to that of other
published studies and enough to estimate the incidence
accurately. We have not performed a stratified analysis by
different groups because our objective was to assess how many
hospital admissions are due to ADR, not how many patients in a
certain group who are seen in the emergency department require
admission. Moreover, in relation to the causality algorithm
application, it is necessary to highlight that there is no
internationally validated algorithm and that the algorithm of
Spanish pharmacovigilance system is only one tool for
evaluation. This type of algorithms depends closely on the
clinical experience and the judgement of the evaluator.CONCLUSIONS
8.4% (95% CI 6.5%–10.3%) of emergency admissions were ADR-
related, most of which were produced at the therapeutic dose,
and this could be explained by the advanced age of our patients
and the high prevalence of comorbidities and polymedication.
The most frequently reported ADR have been opportunistic
infections resulting from antineoplastic and immunomodulatory
treatments, and bleeding caused by antiaggregation and, to a
lesser extent, anticoagulant treatments.May 2020 | Volume 11 | Article 734
Mejı́a et al. Adverse Reactions and Hospital AdmissionSerious ADR account for a significant percentage of emergency
admissions and often affect a fragile andpotentially fatal population
group. Therefore, measures should be established for stricter
control over these patients, monitoring their pathologies and
reducing the number of drugs to the minimum possible.
We found 0.6% (0.08%–1.12%) of emergency admissions
related with medication errors. Although they are difficult to
detect, they are preventable. The solution is within the reach of
health personnel, establishing measures such as: improving
education about the disease for patients and the establishment
of double control over prescriptions.DATA AVAILABILITY STATEMENT
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